Medtronic has launched the Intellis platform with a small implantable spinal cord stimulator for the management of select types of chronic intractable pain in the US.
Following approval from the US Food and Drug Administration (FDA), the Intellis device was implanted in the first patient at the Duke University Medical Centre in North Carolina.
Intended to address the limitations with existing spinal cord stimulation (SCS) systems, the new device leverages the Evolve workflow to balance high-dose (HD) and low-dose (LD) therapy settings.
Medtronic Pain Therapies division senior vice-president and president Marshall Stanton said: “Drawing upon our 40-year legacy in SCS, the launch of the Intellis platform isn't just about a new device, but about combining cutting-edge hardware with optimal therapy through the Evolve workflow to enable personalised, long-term pain relief.
“We considered the entire patient journey starting with the primary goal of optimal pain relief and access to important diagnostic tools, like MRI, to ease of use with simplified programming, faster recharge and a smaller implant.”
The Intellis platform tracks and shares the information on daily activities, body positions and therapy usage to optimise treatment and improve communication between the patient and physician.
It features the firm’s Overdrive battery technology that enables complete recharge in around one hour, SureScan MRI technology for MRI scanning anywhere on the body under select conditions, and AdaptiveStim technology to automatically adjust accurate dose delivery.
The device can be managed on the Samsung Galaxy Tab S2 tablet interface and allows physicians to monitor progress or make modifications to the therapy based on patient needs.
Image: Medtronic's Intellis spinal cord stimulation platform. Photo: courtesy of Medtronic plc.